Results 91 to 100 of about 13,471,027 (144)
Antiarrhythmic potency of procainamide and N-acetylprocainamide in rabbits
European Journal of Pharmacology, 1978 The antiarrhythmic potency of procainamide (PA) and N-acetylprocainamide (NAPA) has been investigated in rabbits using isolated atrial preparations and ouabain-induced ventricular fibrillation in vivo. At concentrations in the range 3 x 10(-5) to 1 x 10(-3) M, both PA and NAPA decreased the maximum following frequency (MFF) of isolated atria. The dose--
Rodney F Minchin +2 more
exaly +6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pharmacokinetics of Procainamide and N-Acetylprocainamide in Rats
Journal of Pharmaceutical Sciences, 1981The pharmacokinetics of distribution and elimination of procainamide and its major metabolite, N-actylprocainamide, were studied in rats. Eight rats were selected randomly, and each received intravenously 14C-labeled procainamide hydrochloride (75 mg/kg) or 14C-labeled N-acetylprocainamide hydrochloride (86 mg/kg) according to a two-way crossover ...
Avraham Yacobi
exaly +3 more sources
Half-life of N-acetylprocainamide in rats
Journal of Pharmaceutical Sciences, 1980Avraham Yacobi
exaly +3 more sources
Pharmacokinetics of N-Acetylprocainamide
Angiology, 1986Shortly after Dreyfus and his colleagues demonstrated that procainamide was metabolized by acetylation to N-acetylprocainamide (NAPA), Drayer, Reidenberg and Sevy reported that NAPA had antiarrhythmic activity in an animal model. We confirmed these findings and found that plasma levels of NAPA were high enough to warrant consideration in managing ...
A J, Atkinson, T I, Ruo
openaire +2 more sources
Clinical Pharmacokinetics of N-acetylprocainamide
Clinical Pharmacokinetics, 1982Since N-acetylprocainamide was identified in the urine of patients receiving procainamide, this compound has been studied both as a metabolite of procainamide and as a separate antiarrhythmic agent. N-acetylprocainamide absorption following oral administration is more than 8-% complete.
S J, Connolly, R E, Kates
openaire +2 more sources
Torsades de Pointes Due to N-Acetylprocainamide
PACE - Pacing and Clinical Electrophysiology, 1985A 66‐year‐old female with chronic renal failure received five doses of procainamide and developed marked QT interval prolongation and recurrent episodes of torsades de pointes. which were temporally related to high serum n‐acetylprocainamide (NAPA) levels and not to procainamide levels.
James N Weiss, W G Stevenson
exaly +3 more sources
Antiarrhythmic potency of N‐acetylprocainamide
Clinical Pharmacology & Therapeutics, 1975Compared to procainamide in an animal arrhythmia model, the antiarrhythmic potency of the N‐acetylated metabolite of procainamide (NAPA) was 92% with respect to dose and 70% with respect to plasma level. The antiarrhythmic effects of combinations of the drugs were additive.
J, Elson +3 more
openaire +2 more sources
Therapeutic Drug Monitoring, 1981
We describe a method for routinely measuring plasma concentrations of procainamide (PA), N-acetylprocainamide (NAPA) and desethyl N-acetylprocainamide (NAPADE) by high-performance liquid chromatography (HPLC). The method has been used together with mass spectrometry of the appropriate chromatographic fraction to demonstrate that NAPADE is a metabolite ...
T I, Ruo +3 more
openaire +2 more sources
We describe a method for routinely measuring plasma concentrations of procainamide (PA), N-acetylprocainamide (NAPA) and desethyl N-acetylprocainamide (NAPADE) by high-performance liquid chromatography (HPLC). The method has been used together with mass spectrometry of the appropriate chromatographic fraction to demonstrate that NAPADE is a metabolite ...
T I, Ruo +3 more
openaire +2 more sources